Skip to main content
. Author manuscript; available in PMC: 2011 Oct 23.
Published in final edited form as: Oncogene. 2008 Sep 22;27(57):7192–7200. doi: 10.1038/onc.2008.356

Figure 5.

Figure 5

Effect of in vivo administration of liposomal-conjugated siRNA to Id2 on CRC tumor growth in the liver. (a) Graphical plot of proton activity from bioluminescence imaging of mice inoculated with 1.0 × 106 HCT-116 cells and imaged at 3, 14 and 28 days after hepatic injection while being treated at 3-day intervals with either control (control siRNA–DOPC) or Id2-specific siRNA (Id2 siRNA– DOPC). (b) Mean tumor volumes at 32 days after inoculation, with continuous intraperitoneal injections every 3 days of control (control siRNA–DOPC) or Id2–specific siRNA (Id2 siRNA–DOPC) (10 mice per group). *P = 0.0045 vs control siRNA. (c) Photographs of excised livers from mice treated with either nonspecific or Id2-targeted siRNA. Id2, inhibitor of DNA-bind-2; siRNA, small interfering RNA; CRC, colorectal cancer; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine.